Attacking Metastasis and Resistance by
Discovering and Targeting Multiple Cancer Survival Pathways
Using Our Systems Biology, Artificial Intelligence-Driven Platform.
 

We De-Risk Therapeutic Development. 
We Increase Patient Reach.
We License Out Our IP to Biopharmaceutical Companies.
 

We are Teaching Our AI to “Think” Like a Biologist.

Our Mission: to make the deadliest cancers survivable.

 



Oncotarget Journal

"Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib"

Kayleigh C. Ross, Kevin F. Chin, Daehwan Kim, Christopher D. Marion, Timothy J. Yen and Vikram Bhattacharjee*
Published Online January 29, 2018. DOI: 10.18632/oncotarget.24341

* - Corresponding Author

 

AACR Journals - Molecular Cancer Therapeutics

"Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells"

Kayleigh C. Ross, Andrew J. Andrews, Christopher D. Marion, Timothy J. Yen and Vikram Bhattacharjee*
Published OnlineFirst May 12, 2017. DOI: 10.1158/1535-7163.MCT-16-0798

* - Corresponding Author